India, May 14 -- Shares of Quoin Pharmaceuticals, Ltd. (QNRX) gained over 25% on Wednesday morning after the late clinical-stage, specialty pharmaceutical company announced initial positive clinical data for QRX003 from the Pediatric Peeling Skin Syndrome study.
QNRX is currently trading at $8.03, up $1.67 or 26.26%, on a huge volume of 7.6 million shares, above the average volume of 211 thousand, on the Nasdaq. The stock opened its trading at $8.75 after closing Tuesday at $6.36. The stock has traded between $5.01 and $54.95 in the past 52-week period.
The company said that after 12 weeks of treatment, clear evidence of skin healing in the area treated with QRX003 compared to baseline was observed.
googletag.cmd.push(function() { google...